ONKURE THERAPEUTICS INC CLASS A (OKUR)
Health Care · Precision oncology / kinase inhibitors · NASDAQ
OnKure develops mutation-selective PI3K inhibitors designed to spare wild-type protein toxicity while targeting cancer-driving mutations in breast cancer and vascular anomalies.
What ONKURE THERAPEUTICS INC CLASS A does
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing precision small-molecule drugs targeting specific mutations in cancer-driver proteins, particularly PI3Kα mutations in breast cancer and vascular anomalies. The company uses structure-based drug design, X-ray crystallography, and computational chemistry to create selective inhibitors that target oncogenic mutant forms of proteins while sparing the wild-type version, aiming to improve efficacy and reduce toxicity. The company's lead candidate OKI-219 is in Phase 1 clinical trials (PIKture-01) for HR+ and HER2+ advanced breast cancer, with next-generation PI3Kα pan-mutant programs (OKI-345 and OKI-355) in preclinical development.
Themes: ["Mutation-selective cancer therapeutics","PI3K pathway inhibition","Precision oncology / breast cancer","Vascular anomalies","Kinase inhibitors"]
Fundamentals
- Price$4.46 as of 2026-07-09 close
- Market cap$180M as of 2026-07-10
- 1-year return+82.1% as of 2026-07-09 close
- ROE-61.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.23 as of 2026-07-10
Key risks (from latest filing)
["Company is clinical-stage with no approved products or product revenue; development may fail or face regulatory delays, and capital requirements are substantial","PI3Kα-targeted therapies face competition from existing PI3K inhibitors and other cancer treatments; clinical development requires continued enrollment and positive efficacy data","Macroeconomic, geopolitical, and regulatory developments including inflation, credit market tightening, and policy changes could adversely affect supply chain, manufacturing, regulatory compliance costs, and approval timelines"]
Competitors & peers
- Arcus Biosciences (ARCUS)
- Array BioPharma (ARRY)
- Principia Biopharma / Sesen Bio
- Ideaya Biosciences (IDYA)
- GlaxoSmithKline (GSK)
- Roche/Genentech
- Novartis (NVS)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.